Haemonetics Corporation 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended December 27, 1997, and the nine-month period ended on the same date. Haemonetics Corporation is a medical technology company focused on blood management systems, including disposable products, equipment, and Blood Bank Management Services (BBMS). The company is incorporated in Massachusetts with principal executive offices in Braintree, MA.
Key Financial Metrics
| Metric | Three Months Ended Dec 27, 1997 | Nine Months Ended Dec 27, 1997 |
|---|---|---|
| Net Revenues | $75.8 million | $234.7 million |
| Gross Profit | $35.5 million (46.8% margin) | $107.1 million (45.6% margin) |
| Operating Income (Loss) | $(17.9) million | $(2.1) million |
| Net Income (Loss) | $(11.7) million | $(1.2) million |
| Diluted EPS | $(0.44) | $(0.04) |
| Cash and Equivalents | $7.3 million (as of Dec 27, 1997) | |
| Total Debt (Current + Long-term) | $72.7 million | |
| Working Capital | $113.8 million |
Material Changes vs. Prior Period
- Revenue: Three-month revenue decreased 1% to $75.8 million, while nine-month revenue increased 4% to $234.7 million. Excluding currency effects, revenue growth was 5% (quarter) and 9% (nine months).
- Profitability: Gross margins declined to 46.8% (quarter) and 45.6% (nine months) from 49.7% and 53.1% in the prior year, respectively. This was driven by higher manufacturing costs, a stronger U.S. dollar, and a shift in product mix toward lower-margin plasma disposables.
- Restructuring Charge: A significant non-recurring restructuring charge of $25.2 million was recorded in the quarter. This included $8.6 million in inventory write-offs, $6.5 million in property/equipment write-downs, and $3.4 million in severance reserves.
- Cash Flow: Operating cash flow turned negative, using $19.4 million for the nine months ended Dec 27, 1997, compared to generating $31.6 million in the prior year period.
Guidance, Outlook, and Risks
- Management Commentary: Management attributes the decline in operating income primarily to the restructuring charge, currency headwinds, and start-up costs associated with the BBMS division. Without the restructuring charge, operating margins would have been 9.7% (quarter) and 9.8% (nine months).
- Liquidity: To fund operations and acquisitions, the company completed a private placement of $40.0 million in unsecured senior notes (7.05% coupon, 10-year term) in October 1997. The revolving credit line was amended to reduce the committed amount from $40.0 million to $20.0 million.
- Acquisitions: The company spent $10.5 million acquiring three blood centers for its BBMS division during the nine-month period.
- Year 2000 Compliance: Management does not anticipate material costs for Year 2000 compliance but notes risks associated with third-party vendors and customers.
- Leadership Change: As of January 30, 1998, James L. Peterson was elected President and CEO, replacing John F. White.
Investor Verification Checklist
- Verify the cash outflow timeline associated with the $25.2 million restructuring charge (estimated total cash utilization of $3.8 million).
- Confirm the impact of the stronger U.S. dollar on future international revenue projections.
- Monitor the integration and profitability timeline of the newly acquired Blood Bank Management Services (BBMS) assets.
- Review the status of the $40.0 million senior note issuance and the reduced $20.0 million revolving credit facility.
- Assess the sustainability of gross margins given the shift from high-margin surgical disposables to lower-margin plasma products.